LENSAR

LENSAR Financial Leverage

The Financial Leverage (Equity Multiplier) of LENSAR (LNSR) as of Oct 21, 2026 is -2.75. In the previous year, Financial Leverage (Equity Multiplier) was 3.56 — a change of -177.21% (lower).

Financial Leverage

-2.75

YoY

-177.21%

Last updated:

Financial Leverage (Equity Multiplier) of LENSAR is 2025 -2.75 . Financial Leverage (Equity Multiplier) of LENSAR was 2024 3.56 . It decreases by -177.21% lower compared to the previous year.

The LENSAR Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
-1.41 USD
Jan 1, 2019
-1.13 USD
Jan 1, 2020
1.18 USD
Jan 1, 2021
1.21 USD
Jan 1, 2022
1.33 USD
Jan 1, 2023
1.48 USD
Jan 1, 2024
3.56 USD
Jan 1, 2025
-2.75 USD
The LENSAR Financial Leverage history
YEARFinancial LeverageYoY
-2.75-177.21%
3.56+141.05%
1.48+10.89%
1.33+9.83%
1.21+2.88%
1.18-204.14%
-1.13-19.91%
-1.41—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LENSAR Stock analysis

What does LENSAR do? LENSAR, Inc. generates revenue through the sale of its femtosecond laser systems, specifically the LENSAR Laser System with Streamline IV and IntelliAxis, and the ALLY Adaptive Cataract Treatment System. The LENSAR Laser System includes disposable patient interface device kits as consumables, which contribute to recurring revenue. Surgeons and ophthalmic clinics purchasing these systems form the primary customer segment, utilizing the technology for cataract surgery and corneal astigmatism management. The company's focus on proprietary technologies ensures differentiation in the medical device market. The ALLY System is marketed as a compact solution for femtosecond laser assisted cataract procedures, designed to streamline surgical workflows within a single operating room. Its product portfolio emphasizes integrated features that enhance visual outcomes for patients. The consumable components, such as the disposable patient interface device kits, support ongoing revenue streams alongside the initial system sales. These offerings target healthcare providers seeking advanced surgical tools for refractive cataract surgery. LENSAR's business model relies on selling high-precision medical devices to specialized healthcare facilities. The LENSAR Laser System and ALLY System are positioned as premium solutions for cataract treatment, with the consumables providing sustained revenue opportunities. The company's product development centers around improving surgical efficiency and patient visual results through its patented technologies. LENSAR is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LENSAR stock

Financial Leverage (Equity Multiplier) of LENSAR is -2.75 in 2025.

Financial Leverage (Equity Multiplier) of LENSAR changed from 3.56 to -2.75, representing a -177.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) LENSAR since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s LENSAR with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — LENSAR

All Key Metrics — LENSAR